MCID: LKM004
MIFTS: 36

Leukemia, B-Cell, Chronic

Categories: Rare diseases, Immune diseases, Cancer diseases, Skin diseases, Blood diseases

Aliases & Classifications for Leukemia, B-Cell, Chronic

MalaCards integrated aliases for Leukemia, B-Cell, Chronic:

Name: Leukemia, B-Cell, Chronic 53
Chronic Lymphocytic Leukemia 73
Chronic B-Cell Leukemia 53

Classifications:



Summaries for Leukemia, B-Cell, Chronic

MalaCards based summary : Leukemia, B-Cell, Chronic, also known as chronic lymphocytic leukemia, is related to leukemia, chronic lymphocytic and leukemia, chronic lymphocytic 2, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia, B-Cell, Chronic is ATM (ATM Serine/Threonine Kinase). The drugs rituximab and Vidarabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Related Diseases for Leukemia, B-Cell, Chronic

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Leukemia, B-Cell, Chronic via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 11.7
2 leukemia, chronic lymphocytic 2 10.2
3 leukemia 10.1

Symptoms & Phenotypes for Leukemia, B-Cell, Chronic

UMLS symptoms related to Leukemia, B-Cell, Chronic:


angina pectoris, chest pain, edema, fatigue

Drugs & Therapeutics for Leukemia, B-Cell, Chronic

Drugs for Leukemia, B-Cell, Chronic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 582)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
2
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
3
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
4
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
5
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53910-25-1 40926 439693
6
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
7
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
8
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
11
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
13
Valganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 175865-60-8 64147
14
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
16 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1 113427-24-0
18 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
20 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
30 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
36 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Bendamustine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1731)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
3 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
4 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
5 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4 chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
6 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
7 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4 Ofatumumab
8 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
9 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
10 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
11 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
12 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
13 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
14 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
15 Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
16 Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
17 Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
18 A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
19 The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Unknown status NCT01518959 Phase 3 Cholecalciferol;oleum neutralicum
20 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
21 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
22 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
23 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
24 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
25 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
26 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
27 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
28 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
29 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
30 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
31 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
32 Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
33 Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
34 Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
35 Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
36 FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
37 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed NCT01500083 Phase 3 Bendamustine at a dose of 100 mg/m2;Bendamustine at a dose of 120 mg/m2
38 Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
39 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients Completed NCT00090051 Phase 3 Rituximab;Fludarabine Phosphate;Cyclophosphamide
40 A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) Completed NCT01580228 Phase 3 Dinaciclib;Ofatumumab
41 A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) Completed NCT01539512 Phase 3 Idelalisib;Rituximab;Placebo to match idelalisib
42 Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia Completed NCT00281892 Phase 3 Fludarabine mono
43 A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
44 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Completed NCT00086580 Phase 3
45 Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia Completed NCT00824265 Phase 3 OFC Infusion;FC infusion
46 Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
47 Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
48 Extension Study of Idelalisib for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116 Completed NCT01539291 Phase 3 Idelalisib
49 Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3 cyclophosphamide;fludarabine phosphate
50 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate

Search NIH Clinical Center for Leukemia, B-Cell, Chronic

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Leukemia, B-Cell, Chronic

Anatomical Context for Leukemia, B-Cell, Chronic

MalaCards organs/tissues related to Leukemia, B-Cell, Chronic:

41
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Kidney, Nk Cells

Publications for Leukemia, B-Cell, Chronic

Articles related to Leukemia, B-Cell, Chronic:

(show top 50) (show all 3406)
# Title Authors Year
1
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
2
Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. ( 29760835 )
2018
3
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. ( 29449433 )
2018
4
A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus. ( 29950535 )
2018
5
Simultaneous finding of chronic lymphocytic leukemia and residual hairy cell leukemia using a lymphocyte-binding anti-CD antibody microarray. ( 29636954 )
2018
6
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia? ( 29402474 )
2018
7
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
8
Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. ( 29976738 )
2018
9
Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. ( 29911929 )
2018
10
Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia. ( 29277764 )
2018
11
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. ( 29450641 )
2018
12
Necrobiotic xanthogranuloma associated with chronic lymphocytic leukemia. ( 29485184 )
2018
13
Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. ( 28565930 )
2018
14
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab. ( 29526963 )
2018
15
Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia. ( 29976737 )
2018
16
Gamma heavy chain disease evolving during the progression of chronic lymphocytic leukemia. ( 29315075 )
2018
17
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. ( 29762141 )
2018
18
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study. ( 29976743 )
2018
19
Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL). ( 29437555 )
2018
20
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
21
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells. ( 29432497 )
2018
22
A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of chronic lymphocytic leukemia cells by altering migration regulatory pathways. ( 29080742 )
2018
23
Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. ( 28679298 )
2018
24
Refractory Abdominal Pain in a Patient with Chronic Lymphocytic Leukemia: Be Wary of Acquired Angioedema due to C1 Esterase Inhibitor Deficiency. ( 29545957 )
2018
25
Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16A years of epidemiological data from the province of Girona, Spain. ( 29383469 )
2018
26
Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro. ( 29353760 )
2018
27
Disseminated cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia. ( 29428267 )
2018
28
Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )
2018
29
Paraneoplastic pemphigus with anti-desmocollin 3 autoantibodies and chronic lymphocytic leukemia. ( 29599682 )
2018
30
Synchronous hairy cell leukemia and chronic lymphocytic leukemia: a case report with a brief review of literature. ( 29963523 )
2018
31
Treatment Sequencing in a Chronic Lymphocytic Leukemia Patient with Central Nervous System Involvement. ( 29977629 )
2018
32
Siglec-6 on chronic lymphocytic leukemia cells is a target for post-allogeneic hematopoietic stem cell transplantation antibodies. ( 29980538 )
2018
33
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome. ( 28708231 )
2017
34
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. ( 28049639 )
2017
35
Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. ( 28240053 )
2017
36
The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia. ( 28349818 )
2017
37
Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. ( 29387498 )
2017
38
Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia. ( 28670081 )
2017
39
Presentation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in a Warthin Tumor: Case Report and Literature Review. ( 28978260 )
2017
40
Paraneoplastic pemphigus associated with chronic lymphocytic leukemia: A case report. ( 28225504 )
2017
41
Venetoclax for the treatment of patients with chronic lymphocytic leukemia. ( 28492339 )
2017
42
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
43
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. ( 28931525 )
2017
44
Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia. ( 28509580 )
2017
45
Possible Role of Polymorphisms in TNFA, NFKB1, and CASP8 Gene Promoter Areas in the Development of Chronic Lymphocytic Leukemia. ( 28361429 )
2017
46
Update of the Grupo EspaA+ol de Leucemia LinfocA-tica CrA^nica clinical guidelines of the management of chronic lymphocytic leukemia. ( 28236475 )
2017
47
New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. ( 28776453 )
2017
48
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia. ( 28503240 )
2017
49
Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes. ( 28888994 )
2017
50
Common nonmutational<i>NOTCH1</i>activation in chronic lymphocytic leukemia. ( 28314854 )
2017

Variations for Leukemia, B-Cell, Chronic

Expression for Leukemia, B-Cell, Chronic

Search GEO for disease gene expression data for Leukemia, B-Cell, Chronic.

Pathways for Leukemia, B-Cell, Chronic

GO Terms for Leukemia, B-Cell, Chronic

Sources for Leukemia, B-Cell, Chronic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....